Cartesian Therapeutics (RNAC) announced a strategic licensing agreement with WestGene Biopharma Co. to advance the development of in vivo chimeric antigen receptor T-cell therapies in autoimmune diseases. Cartesian is partnering with WestGene to conduct a Phase 1 dose-escalation study of the mRNA used in Descartes-08 delivered via WestGenes proprietary targeted lipid nanoparticles in patients with generalized myasthenia gravis.
"Building on our leadership in autologous cell therapy in autoimmune disease, we are partnering with WestGene to extend our mRNA payloads into in vivo delivery, said Carsten Brunn, Ph.D., President and CEO of Cartesian.
WestGene will receive an upfront payment and is eligible to receive potential development and commercial based milestone payments. This clinical study is expected to initiate in second half of 2026 with in-human data expected in first half of 2027.
In pre-market trading on NasdaqGM, Cartesian shares are up 15.74 percent to $6.78.
For More Such Health News, visit rttnews.com.
For comments and feedback contact: editorial@rttnews.com
Business News
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.